Literature DB >> 31364982

Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.

Irene Carrión-Barberà1, Tarek Carlos Salman-Monte1, Sonia Castell1, Francisco Castro-Domínguez1, Fabiola Ojeda1, Jordi Monfort1.   

Abstract

Systemic lupus erythematosus (SLE) is characterized by a wide variety of manifestations and a difficult disease control in some patients. We present the case of a 51-year-old woman who presented with a flare of SLE including arthritis and pleuropericarditis that responded to neither leflunomide, methotrexate, nor high doses of prednisone. After initiating treatment with belimumab, the patient experienced a quick and notorious improvement. She remains stable to this day while continuing belimumab therapy.

Entities:  

Year:  2019        PMID: 31364982      PMCID: PMC6668643          DOI: 10.5152/eurjrheum.2019.17169

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  10 in total

1.  When to use belimumab in SLE.

Authors:  Mariele Gatto; Luca Iaccarino; Margherita Zen; Andrea Doria
Journal:  Expert Rev Clin Immunol       Date:  2017-05-05       Impact factor: 4.473

2.  Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital.

Authors:  Leyre Riancho-Zarrabeitia; Ignacio Villa Blanco; Montserrat Santos-Gómez; Elena Aurrecoechea
Journal:  Reumatol Clin (Engl Ed)       Date:  2018-03-17

3.  Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.

Authors:  M Jüptner; R Zeuner; S Schreiber; M Laudes; J O Schröder
Journal:  Lupus       Date:  2014-01-30       Impact factor: 2.911

Review 4.  Belimumab in the management of systemic lupus erythematosus - an update.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Expert Opin Biol Ther       Date:  2017-05-16       Impact factor: 4.388

5.  The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.

Authors:  Yan Liang; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2016-12-20       Impact factor: 2.631

6.  International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

Authors:  Jean-François Kleinmann; Florence Tubach; Véronique Le Guern; Alexis Mathian; Christophe Richez; David Saadoun; Karim Sacre; Jérémie Sellam; Raphaèle Seror; Zahir Amoura; Emmanuel Andres; Sylvain Audia; Brigitte Bader-Meunier; Gilles Blaison; Bernard Bonnotte; Patrice Cacoub; Sophie Caillard; Laurent Chiche; Olivier Chosidow; Nathalie Costedoat-Chalumeau; Claire Daien; Eric Daugas; Nairouz Derdèche; Andrea Doria; Olivier Fain; Fadi Fakhouri; Dominique Farge; Cem Gabay; Sylvie Guillo; Eric Hachulla; Najia Hajjaj-Hassouni; Mohamed Hamidou; Frédéric A Houssiau; Noémie Jourde-Chiche; Isabelle Koné-Paut; Aïcha Ladjouz-Rezig; Olivier Lambotte; Dan Lipsker; Xavier Mariette; Nicolas Martin-Silva; Thierry Martin; François Maurier; Roderich Meckenstock; Arsène Mékinian; Olivier Meyer; Shirine Mohamed; Jacques Morel; Bruno Moulin; Denis Mulleman; Thomas Papo; Vincent Poindron; Xavier Puéchal; Leonardo Punzi; Pierre Quartier; Laurent Sailler; Amar Smail; Martin Soubrier; Agnès Sparsa; Zoubida Tazi-Mezalek; Leith Zakraoui; Stéphane Zuily; Jean Sibilia; Jacques-Eric Gottenberg
Journal:  Autoimmun Rev       Date:  2017-04-18       Impact factor: 9.754

7.  SER consensus statement on the use of biologic therapy for systemic lupus erythematosus.

Authors:  Jaime Calvo-Alén; Lucía Silva-Fernández; Eduardo Úcar-Angulo; José María Pego-Reigosa; Alejandro Olivé; Carmen Martínez-Fernández; Víctor Martínez-Taboada; José Luis Marenco; Estíbaliz Loza; Javier López-Longo; Juan Jesús Gómez-Reino; María Galindo-Izquierdo; Antonio Fernández-Nebro; María José Cuadrado; María Ángeles Aguirre-Zamorano; Antonio Zea-Mendoza; Iñigo Rúa-Figueroa
Journal:  Reumatol Clin       Date:  2013-07-17

Review 8.  Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.

Authors:  Mariele Gatto; Francesca Saccon; Margherita Zen; Silvano Bettio; Luca Iaccarino; Leonardo Punzi; Andrea Doria
Journal:  J Autoimmun       Date:  2016-06-30       Impact factor: 7.094

9.  Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus.

Authors:  J Zhao; W Bai; P Zhu; X Zhang; S Liu; L Wu; L Ma; L Bi; X Zuo; L Sun; C Huang; X Tian; M Li; Y Zhao; X Zeng
Journal:  Lupus       Date:  2016-01-12       Impact factor: 2.911

10.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Authors:  Ronald F van Vollenhoven; Michelle A Petri; Ricard Cervera; David A Roth; Beulah N Ji; Christi S Kleoudis; Z John Zhong; William Freimuth
Journal:  Ann Rheum Dis       Date:  2012-02-15       Impact factor: 19.103

  10 in total
  1 in total

Review 1.  Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

Authors:  Carlos Rodríguez Escalera; Ángela María Zurita Guisado; Francisco Javier Mateo; Noemí Bahamontes-Rosa; María Jesús García Villanueva
Journal:  Clin Rheumatol       Date:  2022-07-23       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.